Skip to main content
Triangle logo TriangleGet started

Tamoxifen (NCT06075953)

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a one-minute explainerNCT060759531 min

Tamoxifen trial for Ductal Carcinoma in Situ (NCT06075953). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with ductal carcinoma in situ, with at least 50% estrogen- or progesterone-receptor positivity.

The idea: compare usual hormonal therapy with elacestrant, endoxifen, or testosterone/anastrozole. Elacestrant removes estrogen receptors. MRI checks whether continued surveillance is suitable; surgery follows if recommended. The testosterone combination is implanted under the skin; the other treatments are oral.

This phase 2 study plans 400 patients. QuantumLeap sponsors RECAST, with 27 recruiting US sites. Laura Esserman and Kelly Hewitt lead. The study does not establish that surgery can safely be avoided.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.